#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	18930	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2662	875.2	0	.	n	.	0	G1207A	SNP	1207	1207	G	1733	1733	A	1220	A,C,G	1216,2,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	18930	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2662	875.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1976	1976	T	1222	T,C	1219,3	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	18930	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2662	875.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1710	1710	C	1210	C	1210	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	18930	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2662	875.2	0	HET	.	.	.	C326T,A,G	.	326	326	C	852	852	C	1096	C,T,A,G	832,260,2,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32232	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3908	1024.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1844	1844	A	1275	A,G,T	1273,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32232	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3908	1024.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2478	2478	C	1138	C,G,A	1134,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32232	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3908	1024.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2552	2552	A	1079	A,T	1077,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32232	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3908	1024.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3104	3104	C	1173	C,A,T	1170,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	2684	folP	852	852	99.88	folP.l15.c4.ctg.1	2041	163.6	0	.	p	.	0	A204V	NONSYN	610	612	GCA	1172	1174	GTA	253;249;250	G;T;A	253;249;250	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	2684	folP	852	852	99.88	folP.l15.c4.ctg.1	2041	163.6	1	SNP	p	R228S	0	.	.	682	684	CGC	1244	1246	CGC	240;238;239	C,G;G,A,C;C	239,1;236,1,1;239	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	7166	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3984	223.8	0	.	p	.	0	M250I	NONSYN	748	750	ATG	1326	1328	ATA	280;280;281	A,G;T;A,G	279,1;280;280,1	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	7166	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3984	223.8	1	SNP	p	S91F	0	.	.	271	273	TCC	849	851	TCC	294;295;297	T,C;C;C	293,1;295;297	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	7166	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3984	223.8	1	SNP	p	D95N	0	.	.	283	285	GAC	861	863	GAC	308;307;306	G,C,A;A,T;C	306,1,1;306,1;306	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	7166	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3984	223.8	1	SNP	p	D95G	0	.	.	283	285	GAC	861	863	GAC	308;307;306	G,C,A;A,T;C	306,1,1;306,1;306	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	2462	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1919	160.0	0	.	p	.	0	D79N	NONSYN	235	237	GAT	838	840	AAT	288;289;297	A;A;T	288;289;297	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	2462	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1919	160.0	1	SNP	p	G45D	0	.	.	133	135	GGC	736	738	GGC	256;258;257	G;G;C,T	255;257;256,1	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1488	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	1440	128.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	7216	parC	2304	2304	99.65	parC.l15.c4.ctg.1	3464	259.4	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1714	1716	ATC	317;315;314	A;T;C	317;315;314	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	7216	parC	2304	2304	99.65	parC.l15.c4.ctg.1	3464	259.4	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1867	1869	GCA	388;387;389	G,T;C,T;A	387,1;386,1;389	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	7216	parC	2304	2304	99.65	parC.l15.c4.ctg.1	3464	259.4	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2350	2352	ATT	358;355;358	A;T,A;T,A	358;354,1;357,1	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	7216	parC	2304	2304	99.65	parC.l15.c4.ctg.1	3464	259.4	1	SNP	p	D86N	0	.	.	256	258	GAC	820	822	GAC	308;309;312	G,C;A;C	307,1;309;312	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	7216	parC	2304	2304	99.65	parC.l15.c4.ctg.1	3464	259.4	1	SNP	p	S87I	0	.	.	259	261	AGT	823	825	AGT	315;316;318	A,T,C;G;T,G,C	313,1,1;316;315,2,1	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	7216	parC	2304	2304	99.65	parC.l15.c4.ctg.1	3464	259.4	1	SNP	p	S87W	0	.	.	259	261	AGT	823	825	AGT	315;316;318	A,T,C;G;T,G,C	313,1,1;316;315,2,1	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	7216	parC	2304	2304	99.65	parC.l15.c4.ctg.1	3464	259.4	1	SNP	p	S87R	0	.	.	259	261	AGT	823	825	AGT	315;316;318	A,T,C;G;T,G,C	313,1,1;316;315,2,1	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	7216	parC	2304	2304	99.65	parC.l15.c4.ctg.1	3464	259.4	1	SNP	p	S88P	0	.	.	262	264	TCC	826	828	TCC	322;323;327	T,A,C;C,T;C,G	320,1,1;321,1;325,1	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5392	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3083	217.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1755	1757	GGC	296;295;294	G;G;C	296;295;294	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.002	penA.2.002	1	1	27	5118	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2891	220.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1510	1512	GCA	281;279;278	G;C;A,T	281;279;277,1	penA.2.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	5118	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2891	220.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1513	1515	ATC	281;278;283	A;T,C;C,T,A	281;277,1;281,1,1	penA.2.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	5118	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2891	220.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1525	1527	GTG	284;288;291	G;T;G	283;287;291	penA.2.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	5118	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2891	220.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1525	1527	GTG	284;288;291	G;T;G	283;287;291	penA.2.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	5118	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2891	220.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2029	2031	ACC	295;297;300	A,G;C,A;C	294,1;296,1;300	penA.2.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	5118	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2891	220.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2083	2085	GCG	266;269;271	G,A,T;C,G;G,A,C	264,1,1;268,1;269,1,1	penA.2.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	5118	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2891	220.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2083	2085	GCG	266;269;271	G,A,T;C,G;G,A,C	264,1,1;268,1;269,1,1	penA.2.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	5118	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2891	220.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2206	2208	GGC	298;302;302	G,T,C;G;C	296,1,1;302;302	penA.2.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	5118	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2891	220.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2215	2217	GGC	300;302;301	G;G;C,G	300;302;300,1	penA.2.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	5118	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2891	220.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2233	2235	CCG	298;298;298	C,G;C;G,C	296,2;298;297,1	penA.2.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	7122	ponA	2397	2397	99.87	ponA.l15.c4.ctg.1	3584	247.4	0	.	p	.	0	P750L	NONSYN	2248	2250	CCT	2872	2874	CTT	279;280;282	C;T;T,A	278;279;281,1	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	3290	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2419	169.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	878	878	C	268	C	268	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	3694	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1729	260.9	0	.	p	.	0	A29V	NONSYN	85	87	GCC	525	527	GTC	288;289;287	G;T,G;C	288;288,1;287	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	3694	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1729	260.9	0	.	p	.	0	T50A	NONSYN	148	150	ACT	588	590	GCT	292;289;295	G,T,A;C,A;T	290,1,1;288,1;295	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	3694	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1729	260.9	0	.	p	.	0	K88L	NONSYN	262	264	AAA	702	704	CTC	291;293;294	C;T;C,G	291;293;293,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	3694	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1729	260.9	0	.	p	.	0	S93N	NONSYN	277	279	AGC	717	719	AAC	300;301;301	A,G;A;C	299,1;301;301	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	3694	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1729	260.9	0	.	p	.	0	H111R	NONSYN	331	333	CAT	771	773	CGT	296;291;289	C,T;G;T	295,1;291;289	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	3694	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1729	260.9	0	.	p	.	0	N114S	NONSYN	340	342	AAC	780	782	AGC	290;287;291	A,G;G;C	289,1;287;291	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	3694	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1729	260.9	0	.	p	.	0	I115V	NONSYN	343	345	ATC	783	785	GTC	291;293;292	G;T;C,T	291;293;291,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	3694	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1729	260.9	0	.	p	.	0	D120G	NONSYN	358	360	GAC	798	800	GGC	301;303;304	G,A;G;C,A	300,1;303;303,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	3694	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1729	260.9	0	.	p	.	0	Y201F	NONSYN	601	603	TAC	1041	1043	TTC	305;305;305	T,G;T,C;C	303,2;304,1;305	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	3694	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1729	260.9	0	.	p	.	0	S236R	NONSYN	706	708	AGC	1146	1148	CGC	325;326;330	C;G;C,A	323;324;327,1	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	12444	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5363	288.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2194	2196	CAT	311;312;311	C,G,A;A,C;T,A	309,1,1;309,2;309,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1768	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1526	144.4	1	SNP	p	V57M	0	.	.	169	171	GTG	728	730	GTG	302;303;303	G;T,A;G,C	302;302,1;302,1	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
